The evolution of tissue engineered vascular graft technologies: From preclinical trials to advancing patient care

99Citations
Citations of this article
227Readers
Mendeley users who have this article in their library.

Abstract

Currently available synthetic grafts have contributed to improved outcomes in cardiovascular surgery. However, the implementation of these graft materials at small diameters have demonstrated poor patency, inhibiting their use for coronary artery bypass surgery in adults. Additionally, when applied to a pediatric patient population, they are handicapped by their lack of growth ability. Tissue engineered alternatives could possibly address these limitations by producing biocompatible implants with the ability to repair, remodel, grow, and regenerate. A tissue engineered vascular graft (TEVG) generally consists of a scaffold, seeded cells, and the appropriate environmental cues (i.e., growth factors, physical stimulation) to induce tissue formation. This review critically appraises current state-of-the-art techniques for vascular graft production. We additionally examine current graft shortcomings and future prospects, as they relate to cardiovascular surgery, from two major clinical trials.

Cite

CITATION STYLE

APA

Matsuzaki, Y., John, K., Shoji, T., & Shinoka, T. (2019, April 1). The evolution of tissue engineered vascular graft technologies: From preclinical trials to advancing patient care. Applied Sciences (Switzerland). MDPI AG. https://doi.org/10.3390/app9071274

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free